Mixed amphetamine salts half-life
The mixed-salts profile keeps the labeled difference between d-amphetamine and l-amphetamine visible.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Mixed amphetamine salts: evidence and interpretation notes
What the curve is actually following
The mixed-salts profile keeps the labeled difference between d-amphetamine and l-amphetamine visible. Its 11.5-hour midpoint is a charting convenience across the 10-to-13-hour stereoisomer estimates, not a new measured analyte.
The calculator follows Mixed d- and l-amphetamine estimate with a 11.5-hour half-life. That simplification is useful for curve shape and comparison, but it is not an individualized pharmacokinetic estimate.
Mixed amphetamine salts can vary with formulation, route, metabolism, urine pH, and active metabolites. The curve visualizes a selected pharmacokinetic value rather than alertness, cardiovascular effects, sleep disruption, or performance.
What each source contributes
- DailyMed: ADDERALL XR (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE) CAPSULE, EXTENDED RELEASE [TAKEDA PHARMACEUTICALS AMERICA, INC.]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Mixed amphetamine salts. This identity record confirms names and compound identity and does not supply a human half-life.
- Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Mixed amphetamine salts, the numerical model is tied most closely to DailyMed: ADDERALL XR (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE) CAPSULE, EXTENDED RELEASE [TAKEDA PHARMACEUTICALS AMERICA, INC.]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 10-to-13-hour range is retained beside the 11.5-hour input for Mixed d- and l-amphetamine estimate. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 11.5 h as a representative input for Mixed d- and l-amphetamine estimate. In the simplified model, about 23.5% remains after 24 hours and about 3% remains after five half-lives, or roughly 2.4 days.
This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
ComparisonTimeline checkpoints and nearby profiles
Mixed amphetamine salts timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 12 h | 48.5% | Meaningful modeled decline, not near-zero |
| 24 h | 23.5% | Long-tail portion of the model |
| 2.0 days | 5.54% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 1.30% | Low modeled remainder, not a clearance guarantee |
| 5.0 days | 0.07% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Mixed amphetamine salts within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Methamphetamine (11 h)
- Dextroamphetamine (11 h)
- Amphetamine (11 h)
- Caffeine (5 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 11.5 h |
|---|---|
| Modeled analyte or phase | Mixed d- and l-amphetamine estimate |
| Reported range | 10 h to 13 h |
| Curve type | Normalized, first-order decline |
Selection note: The mixed-salts profile keeps the labeled difference between d-amphetamine and l-amphetamine visible. Its 11.5-hour midpoint is a charting convenience across the 10-to-13-hour stereoisomer estimates, not a new measured analyte.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: ADDERALL XR (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE) CAPSULE, EXTENDED RELEASE [TAKEDA PHARMACEUTICALS AMERICA, INC.].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Mixed amphetamine salts.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.